---
title: "InMed Gains 4.53% on Alzheimer's Program Update; Medicus Pharma's SkinJect™ Shows Promise"
canonical_url: https://www.stockexpertai.com/journal/2026-03-09/inmed-gains-453-on-alzheimers-program-update-medicus-pharmas-skinject-shows-promise-2
last_updated: 2026-03-09T12:15:16.608Z
section: "Earnings Watch"
author: "Taylor Brooks"
publisher: Stock Expert AI
tickers: INM, MEDP, SBET, GBTG
content_type: journal-article
---

# InMed Gains 4.53% on Alzheimer's Program Update; Medicus Pharma's SkinJect Shows Promise

## The Take
- Pharma investors should monitor INM and MEDP clinical trial progress; Nayax's guidance suggests continued growth in payment tech.

_Pharma sector sees positive developments; Nayax issues optimistic 2026 revenue guidance._

Earnings season brings clarity—and volatility. Today's focus shifts to the pharmaceutical and payment technology sectors, where recent announcements are driving investor sentiment. InMed Pharmaceuticals (INM) is making strides in its Alzheimer's and age-related macular degeneration programs, while Medicus Pharma (MEDP) is reporting positive Phase 2 data. Separately, Nayax has released full-year results and provided forward-looking guidance.

InMed Pharmaceuticals (INM) is advancing its Alzheimer's program, with lead drug candidate INM-901, and its age-related macular degeneration program, with INM-405. The company is moving towards IND-enabling activities, targeting the initiation of Phase 1 clinical trials for Alzheimer's disease in 2027. The news seems to be well-received, as INM shares are up +4.53% today. Medicus Pharma (MEDP) is also in focus after reporting 73% clinical clearance in the 200-µg cohort of its Phase 2 SkinJect study at Day 57. MEDP shares show a modest gain of +0.26% following the news.

Outside of pharmaceuticals, Nayax reported full-year revenue of $400.4 million and recurring revenue growth of 29%. Net income reached $35.5 million with an Adjusted EBITDA of $61.1 million. The company is optimistic about 2026, providing revenue guidance of $510 million to $520 million. While Nayax's ticker is not directly tracked in this update, the positive guidance suggests continued growth in the payment technology sector.

SBET (Sharplink) is anticipated to release its Q4 earnings report, with expectations yet to be seen. GBTG's Q3 results showed an EPS Actual of -$0.13 compared to an EPS Estimate of 0.08, while the Revenue Actual was $674.00M compared to a Revenue Estimate of 615.37M, showing a mixed performance. Expectations are set. Now comes execution.

## Related Tickers
- [INM](https://www.stockexpertai.com/stock/inm)
- [MEDP](https://www.stockexpertai.com/stock/medp)
- [SBET](https://www.stockexpertai.com/stock/sbet)
- [GBTG](https://www.stockexpertai.com/stock/gbtg)

## Frequently Asked Questions

### What is driving InMed Pharmaceuticals (INM) stock price today?
InMed Pharmaceuticals (INM) shares are up due to positive updates on their Alzheimer's and age-related macular degeneration programs. The company is progressing towards Phase 1 clinical trials for its Alzheimer's drug candidate, INM-901, which has investors optimistic about future developments.

### What is the latest news from Medicus Pharma (MEDP)?
Medicus Pharma (MEDP) reported positive Phase 2 data for its SkinJect™ study, showing a 73% clinical clearance in the 200-µg cohort. This positive data has resulted in a modest gain in MEDP shares, indicating investor confidence in the company's progress.

---
_AI-generated under human editorial supervision. Educational research, not financial advice._